A Validated, Specific Stability-Indicating RP-LC Method for Moxifloxacin and Its Related Substances
- 302 Downloads
A validated, specific, stability-indicating reversed-phase liquid chromatographic method has been developed for quantitative analysis of moxifloxacin and its related substances in bulk samples and pharmaceutical dosage forms in the presence of degradation products and process-related impurities. Forced degradation studies were performed on bulk samples of moxifloxacin, in accordance with ICH guidelines, using acidic, basic, and oxidizing conditions, and thermal and photolytic stress, to show the stability-indicating power of the method. Significant degradation was caused by oxidative stress and by basic conditions; no degradation was observed under the other stress conditions. The method was optimized by analysis of the samples generated during the forced degradation studies and sample solutions spiked with the impurities. Good resolution between the analyte peak and peaks corresponding to process-related impurities and degradation products was achieved on a C18 column with a simple linear mobile phase gradient prepared from aqueous sodium dihydrogen orthophosphate dihydrate containing triethylamine, pH adjusted to 3.0 with orthophosphoric acid, and methanol. Detection was performed at 240 nm. Limits of detection and quantification were established for moxifloxacin and its process related impurities. When the stressed test solutions were assayed against moxifloxacin working standard solution the mass balance was always between 99.3 and 100.1%, indicating the method was stability-indicating. The method was validated in accordance with ICH guidelines, and found to be suitable for checking the quality of bulk samples of moxifloxacin at the time of release of a batch and during storage (long term and accelerated stability testing was conducted).
KeywordsColumn liquid chromatography Forced degradation RSD and validation Moxifloxacin
The authors wish to thank the management of United States Pharmacopeia-India Private Limited group for supporting this work. We would also like to thank colleagues in separation science division of Analytical Research of United States Pharmacopeia-India Private Limited for their cooperation in carrying out this work.
- 3.Lorian V (ed) (1996) Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins, Baltimore, pp 591–592Google Scholar
- 4.Samanidou VF, Demetriou CE, Papadoyannis IN (2003) Anal Bioanal Chem 375:623–629Google Scholar
- 8.ICH (1994) Text on validation of analytical procedures, Q2A, International Conference on Harmonization, IFPMA, GenevaGoogle Scholar
- 10.ICH (1996) Photostability testing of new drug substances and products Q1B, International Conference on Harmonization, IFPMA, GenevaGoogle Scholar
- 11.Draft International Harmonization of Pharmacopoeias (1993) Text on validation of analytical procedures. Pharmaeuropa 5(4):341Google Scholar
- 13.United States Pharmacopeia (2000) Validation of compendial methods, 24th edn. USP 24, Sect. 1225Google Scholar
- 14.Centre for Drug Evaluation and Research (1994) Validation of chromatographic methods; reviewer guidance. Centre for Drug Evaluation and research (CDER), November 1994, CMC 3Google Scholar
- 15.ICH (2003) Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization, IFPMA, GenevaGoogle Scholar